Taiwan’s biotechnology industry was valued at USD 3.3 billion in 2016, representing around 26 percent of the island’s total biopharmaceutical market, along with pharmaceuticals and medical devices.
The stock market capitalization of Taiwan’s biotech sector soared from USD 3.4 billion in 2007 to USD 21 billion 2013. In 2017 it stood at USD 23.8 billion, slightly down on a high of USD 25 billion in 2015. The number of listed biotech companies in Taiwan has grown year-on-year in the same period, from 39 in 2007 to 114 in 2017.
The 120 biotechs that were registered on the Taiwan stock exchange in 2018 had a market value of USD 23.4 billion and generated USD 7.64 billion of revenue.